SCHEMBL5124141

SCHEMBL5124141

Cc1sc2nc(-n3cncn3)nc(NCCc3ccc4c(c3)OCO4)c2c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 1/20 0.41
PDE5A O76074 1/20 0.39
FLT1 P17948 3/20 0.38
KDR P35968 3/20 0.38
NOS2 P35228 3/20 0.38
CHRM4 P08173 1/20 0.37
NOS1 P29475 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
PPP1CA P62136 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128280 0.92 CHRM4 (0.41) PDE5ACHRM4ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL5128666 0.92 BCDIN3D (0.42) BCDIN3DPDE5AFLT1KDRNOS2
SCHEMBL5128977 0.87 BCDIN3D (0.40) BCDIN3DPDE5AFLT1KDRNOS2
SCHEMBL5120030 0.86 CHRM4 (0.42) PDE5ACHRM4ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL5128996 0.86 NOS2 (0.53) NOS2NOS1
SCHEMBL5124266 0.85 BCDIN3D (0.42) BCDIN3DPDE5AFLT1KDRNOS2
SCHEMBL5122859 0.84 BCDIN3D (0.43) BCDIN3DPDE5AFLT1KDRNOS2
SCHEMBL5122862 0.84 BCDIN3D (0.45) BCDIN3DPDE5AFLT1KDRNOS2
SCHEMBL5777505 0.83 ALDH1A1 (0.44) BCDIN3DALDH1A1HSD17B10SMN1; SMN2LMNA
SCHEMBL5118395 0.83 PDE5A (0.43) BCDIN3DPDE5AFLT1KDRCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 BCDIN3D 1161/4885PDE5A 2002/4885FLT1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.